Cirrhosis, Liver Clinical Trial
Official title:
The Acceptability of an App-based, Interactive, Personalized Nutrition and Exercise Program to Support Self-management in Cirrhosis: a Pilot Study
Verified date | January 2023 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The personalized nutrition and exercise app was designed for use by individuals living with chronic conditions. The pilot study examines the acceptance and use of the online, interactive program to support self-management in cirrhosis.
Status | Completed |
Enrollment | 27 |
Est. completion date | December 31, 2022 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adult (aged 18 years and older) - diagnosis of cirrhosis (MELD<25) according to biopsy, imaging, elastography, or other - fulfill the guideline-based prophylaxis in place for high risk gastroesophageal varices - able to communicate (e.g., speak, read, and write) in English - provide informed written consent for self Exclusion Criteria: - hepatocellular carcinoma (HCC) outside of the Edmonton liver transplant criteria - previous myocardial infarction - EF <50% - ischemia on stress testing - oxygen saturation <95% - non-HCC malignancy - end-stage renal disease. - at the discretion of the healthcare team if a participant can participate in the pilot study |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Canadian National Transplant Research Program, Nutricia Foundation |
Canada,
Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans. Liver Int. 2018 Oct;38(10):1706-1717. doi: 10.1111/liv.13876. Epub 2018 May 25. — View Citation
Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. Liver Transpl. 2017 Nov;23(11):1451-1464. doi: 10.1002/lt.24848. — View Citation
Ney M, Gramlich L, Mathiesen V, Bailey RJ, Haykowsky M, Ma M, Abraldes JG, Tandon P. Patient-perceived barriers to lifestyle interventions in cirrhosis. Saudi J Gastroenterol. 2017 Mar-Apr;23(2):97-104. doi: 10.4103/1319-3767.203357. — View Citation
Ney M, Haykowsky MJ, Vandermeer B, Shah A, Ow M, Tandon P. Systematic review: pre- and post-operative prognostic value of cardiopulmonary exercise testing in liver transplant candidates. Aliment Pharmacol Ther. 2016 Oct;44(8):796-806. doi: 10.1111/apt.13771. Epub 2016 Aug 19. — View Citation
Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, Holman J, Howes N, Haykowsky MJF, Josbeno DA, McNeely M. Exercise in cirrhosis: Translating evidence and experience to practice. J Hepatol. 2018 Nov;69(5):1164-1177. doi: 10.1016/j.jhep.2018.06.017. Epub 2018 Jun 30. — View Citation
Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, Ma M, Abraldes JG, Paterson I, Haykowsky MJ, Tandon P. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1920-6.e2. doi: 10.1016/j.cgh.2014.04.016. Epub 2014 Apr 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Chair Sit-to-Stand | The change in time required to complete 5x sit-to-stands from baseline to end of study. | 12 weeks | |
Other | Thigh Muscle Measures | The change in thigh muscle thickness and echogenicity from baseline to end of study. | 12 weeks | |
Primary | Participant Retention/Adherence | The number of participants who complete the 12-week nutrition and exercise program and meet 70% of the nutrition and exercise goals. | 12 weeks | |
Secondary | 6-MWT | The change in distance walked in 6 minutes. | 12 weeks | |
Secondary | Program Satisfaction | Self-reported satisfaction with the nutrition and exercise program. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Completed |
NCT04604860 -
Use of EL-FIT App to Promote Physical Activity
|
N/A | |
Recruiting |
NCT05928624 -
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients
|
N/A | |
Active, not recruiting |
NCT01438970 -
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
|
Phase 2 | |
Recruiting |
NCT05998330 -
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
|
N/A | |
Completed |
NCT04581369 -
Cirrhosis Medical Home
|
N/A | |
Withdrawn |
NCT04244877 -
Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility
|
Phase 3 | |
Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
Recruiting |
NCT05538962 -
Longitudinal Monitoring of Inflammation in Cirrhosis
|
N/A | |
Completed |
NCT04082780 -
Rifamycin in Minimal Hepatic Encephalopathy
|
Phase 2 | |
Completed |
NCT03850977 -
Is There an Association Between Chronic Pancreatitis and Pulmonary Function
|
||
Active, not recruiting |
NCT03736265 -
Carvedilol for Prevention of Esophageal Varices Progression
|
N/A | |
Recruiting |
NCT04530760 -
Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation
|
||
Recruiting |
NCT05093218 -
Effect of Branch Chain Amino Acid Therapy on Sarcopenia in Children With Chronic Liver Disease.
|
N/A | |
Recruiting |
NCT03437876 -
Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis
|
N/A | |
Recruiting |
NCT05604274 -
Longitudinal Monitoring of Stool Characteristics
|
||
Recruiting |
NCT04867954 -
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
|
||
Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT04121520 -
Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
|